FIGURE 1-1 Constraints and limitations of the four-part life cycle of the pharmaceutical drug benefit–risk assessment process.

SOURCE: Adapted from Jeffrey Leiden’s presentation.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement